This document outlines details of PBS-subsidised azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings and Processing Written Authority approval requests.
Acute myeloid leukaemia (AML) quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial
|
Telephone
Electronic
S100:
azacitidine injection
S85:
decitabine+cedazuridine (general listing)
|
No |
OPA |
Not specified |
Yes |
|
Continuing
|
Streamlined
S100:
azacitidine injection
S85:
decitabine+cedazuridine (general listing)
|
No |
N/A |
Not specified
|
N/A |
|
Induction consolidation
|
Telephone
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Initial maintenance
PB253 form |
Written
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Continuing
maintenance
|
Telephone
Electronic
S100:
midostaurin
|
No |
OPA |
Not specified |
Yes |
|
Initial treatment
following intensive induction chemotherapy
|
Telephone
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Continuing treatment
following intensive induction chemotherapy
|
Telephone
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Continuing treatment
Dose escalation therapy
PB355 form
|
Written
Electronic
S85:
azacitidine tablet
|
No |
OPA |
Not specified |
Yes |
|
Induction |
Telephone
Electronic
S100:
daunorubicin+cytarabine |
No |
OPA |
Not specified |
Yes |
|
Consolidation |
Telephone
Electronic
S100:
daunorubicin+cytarbine |
No |
OPA |
Not specified |
Yes |
Expand all